These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

94 related articles for article (PubMed ID: 27012630)

  • 1. Partial neurorescue effects of DHA following a 6-OHDA lesion of the mouse dopaminergic system.
    Coulombe K; Saint-Pierre M; Cisbani G; St-Amour I; Gibrat C; Giguère-Rancourt A; Calon F; Cicchetti F
    J Nutr Biochem; 2016 Apr; 30():133-42. PubMed ID: 27012630
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Neuroprotective and neurorescue effect of black tea extract in 6-hydroxydopamine-lesioned rat model of Parkinson's disease.
    Chaturvedi RK; Shukla S; Seth K; Chauhan S; Sinha C; Shukla Y; Agrawal AK
    Neurobiol Dis; 2006 May; 22(2):421-34. PubMed ID: 16480889
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Characterization of a new low-dose 6-hydroxydopamine model of Parkinson's disease in rat.
    Penttinen AM; Suleymanova I; Albert K; Anttila J; Voutilainen MH; Airavaara M
    J Neurosci Res; 2016 Apr; 94(4):318-28. PubMed ID: 26762168
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Nerve growth factor increases survival of dopaminergic graft, rescue nigral dopaminergic neurons and restores functional deficits in rat model of Parkinson's disease.
    Chaturvedi RK; Shukla S; Seth K; Agrawal AK
    Neurosci Lett; 2006 May; 398(1-2):44-9. PubMed ID: 16423459
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Naringin treatment induces neuroprotective effects in a mouse model of Parkinson's disease in vivo, but not enough to restore the lesioned dopaminergic system.
    Kim HD; Jeong KH; Jung UJ; Kim SR
    J Nutr Biochem; 2016 Feb; 28():140-6. PubMed ID: 26878791
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Docosahexaenoic acid promotes dopaminergic differentiation in induced pluripotent stem cells and inhibits teratoma formation in rats with Parkinson-like pathology.
    Chang YL; Chen SJ; Kao CL; Hung SC; Ding DC; Yu CC; Chen YJ; Ku HH; Lin CP; Lee KH; Chen YC; Wang JJ; Hsu CC; Chen LK; Li HY; Chiou SH
    Cell Transplant; 2012; 21(1):313-32. PubMed ID: 21669041
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impact of DHA intake in a mouse model of synucleinopathy.
    Coulombe K; Kerdiles O; Tremblay C; Emond V; Lebel M; Boulianne AS; Plourde M; Cicchetti F; Calon F
    Exp Neurol; 2018 Mar; 301(Pt A):39-49. PubMed ID: 29229294
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Neurorescue effects of VEGF on a rat model of Parkinson's disease.
    Yasuhara T; Shingo T; Muraoka K; Kameda M; Agari T; Wen Ji Y; Hayase H; Hamada H; Borlongan CV; Date I
    Brain Res; 2005 Aug; 1053(1-2):10-8. PubMed ID: 16045899
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A partial lesion model of Parkinson's disease in mice--characterization of a 6-OHDA-induced medial forebrain bundle lesion.
    Boix J; Padel T; Paul G
    Behav Brain Res; 2015 May; 284():196-206. PubMed ID: 25698603
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Social enrichment attenuates nigrostriatal lesioning and reverses motor impairment in a progressive 1-methyl-2-phenyl-1,2,3,6-tetrahydropyridine (MPTP) mouse model of Parkinson's disease.
    Goldberg NR; Fields V; Pflibsen L; Salvatore MF; Meshul CK
    Neurobiol Dis; 2012 Mar; 45(3):1051-67. PubMed ID: 22198503
    [TBL] [Abstract][Full Text] [Related]  

  • 11. High frequency stimulation of subthalamic nucleus results in behavioral recovery by increasing striatal dopamine release in 6-hydroxydopamine lesioned rat.
    He Z; Jiang Y; Xu H; Jiang H; Jia W; Sun P; Xie J
    Behav Brain Res; 2014 Apr; 263():108-14. PubMed ID: 24462728
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Chronic, systemic treatment with a metabotropic glutamate receptor 5 antagonist in 6-hydroxydopamine partially lesioned rats reverses abnormal firing of dopaminergic neurons.
    Chen L; Zhang QJ; Liu J; Wang S; Ali U; Gui ZH; Wang Y
    Brain Res; 2009 Aug; 1286():192-200. PubMed ID: 19545547
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Additive neurorestorative effects of exercise and docosahexaenoic acid intake in a mouse model of Parkinson's disease.
    Kerdiles O; Oye Mintsa Mi-Mba MF; Coulombe K; Tremblay C; Émond V; Saint-Pierre M; Rouxel C; Berthiaume L; Julien P; Cicchetti F; Calon F
    Neural Regen Res; 2025 Feb; 20(2):574-586. PubMed ID: 38819068
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Systemically administered neuregulin-1β1 rescues nigral dopaminergic neurons via the ErbB4 receptor tyrosine kinase in MPTP mouse models of Parkinson's disease.
    Depboylu C; Rösler TW; de Andrade A; Oertel WH; Höglinger GU
    J Neurochem; 2015 May; 133(4):590-7. PubMed ID: 25581060
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impact of the lesion procedure on the profiles of motor impairment and molecular responsiveness to L-DOPA in the 6-hydroxydopamine mouse model of Parkinson's disease.
    Francardo V; Recchia A; Popovic N; Andersson D; Nissbrandt H; Cenci MA
    Neurobiol Dis; 2011 Jun; 42(3):327-40. PubMed ID: 21310234
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The antioxidant drink effective microorganism-X (EM-X) pre-treatment attenuates the loss of nigrostriatal dopaminergic neurons in 6-hydroxydopamine-lesion rat model of Parkinson's disease.
    Datla KP; Bennett RD; Zbarsky V; Ke B; Liang YF; Higa T; Bahorun T; Aruoma OI; Dexter DT
    J Pharm Pharmacol; 2004 May; 56(5):649-54. PubMed ID: 15142343
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The influence and the mechanism of docosahexaenoic acid on a mouse model of Parkinson's disease.
    Ozsoy O; Seval-Celik Y; Hacioglu G; Yargicoglu P; Demir R; Agar A; Aslan M
    Neurochem Int; 2011 Oct; 59(5):664-70. PubMed ID: 21736911
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Histological, behavioural and neurochemical evaluation of medial forebrain bundle and striatal 6-OHDA lesions as rat models of Parkinson's disease.
    Yuan H; Sarre S; Ebinger G; Michotte Y
    J Neurosci Methods; 2005 May; 144(1):35-45. PubMed ID: 15848237
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Rho kinase inhibition by fasudil in the striatal 6-hydroxydopamine lesion mouse model of Parkinson disease.
    Tatenhorst L; Tönges L; Saal KA; Koch JC; Szegő ÉM; Bähr M; Lingor P
    J Neuropathol Exp Neurol; 2014 Aug; 73(8):770-9. PubMed ID: 25003236
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluation of chronic omega-3 fatty acids supplementation on behavioral and neurochemical alterations in 6-hydroxydopamine-lesion model of Parkinson's disease.
    Delattre AM; Kiss A; Szawka RE; Anselmo-Franci JA; Bagatini PB; Xavier LL; Rigon P; Achaval M; Iagher F; de David C; Marroni NA; Ferraz AC
    Neurosci Res; 2010 Mar; 66(3):256-64. PubMed ID: 19941911
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.